Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 1;64(11):1597-1603.
doi: 10.1093/cid/cix194.

Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations

Martina Penazzato  1 , Devasena Gnanashanmugam  2 , Pablo Rojo  3   4 , Marc Lallemant  5 , Linda L Lewis  6 , Francesca Rocchi  4 , Agnes Saint Raymond  7 , Nathan Ford  1 , Rohan Hazra  8 , Carlo Giaquinto  9 , Yodit Belew  10 , Diana M Gibb  11 , Elaine J Abrams  12   13 ; Paediatric Antiretroviral Working Group (PAWG)
Collaborators, Affiliations
Review

Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations

Martina Penazzato et al. Clin Infect Dis. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Clin Infect Dis. 2017 Oct 15;65(8):1431-1433. doi: 10.1093/cid/cix563. Clin Infect Dis. 2017. PMID: 29017252 Free PMC article. No abstract available.

Abstract

Globally 1.8 million children are living with human immunodeficiency virus (HIV), yet only 51% of those eligible actually start treatment. Research and development (R&D) for pediatric antiretrovirals (ARVs) is a lengthy process and lags considerably behind drug development in adults. Providing safe, effective, and well-tolerated drugs for children remains critical to ensuring scale-up globally. We review current approaches to R&D for pediatric ARVs and suggest innovations to enable simplified, faster, and more comprehensive strategies to develop optimal formulations. Several approaches could be adopted, including focusing on a limited number of prioritized formulations and strengthening existing partnerships to ensure that pediatric investigation plans are developed early in the drug development process. Simplified and more efficient mechanisms to undertake R&D need to be put in place, and financing mechanisms must be made more sustainable. Lessons learned from HIV should be shared to support progress in developing pediatric formulations for other diseases, including tuberculosis and viral hepatitis.

Keywords: HIV; antiretrovirals; children; formulations; research.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Development and introduction of fixed-dose combinations for children living with human immunodeficiency virus. Abbreviations: ARV, antiretroviral; FDC, fixed-dose combination; PK, pharmacokinetic; SOC, standard of care; SRA, stringent regulatory authorities; Tx, treatment.
Figure 2.
Figure 2.
Strategies to innovate research and speed up collection of critical data to develop and introduce pediatric drug and formulations more rapidly. Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus; PIP, pediatric investigation plan; PK, pharmacokinetic; PSP, pediatric study plan; WHO, World Health Organization.
Figure 3.
Figure 3.
Translating novel approaches: potential immediate applications to the development of dolutegravir/tenofovir alafenamide/emtricitabine. Abbreviations: DTG, dolutegravir; EMA, European Medicines Agency; FDA, Food and Drug Administration; FDC, fixed-dose combination; F/TAF, emtricitabine/tenofovir alafenamide; FTC, emtricitabine; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trials; LBW, low birth weight; MPP, medicines patent pool; PHTI, Paediatric HIV Treatment Initiative; PK, pharmacokinetic; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
See this image and copyright information in PMC

References

    1. Joint United Nations Programme on HIV/AIDS. Global AIDS response progress reporting 2016 Geneva, Switzerland: UNAIDS, 2016. - PubMed
    1. Joint United Nations Programme on HIV/AIDS. Prevention gap report, July 2016 Geneva, Switzerland: UNAIDS, 2016. Available at: http://www.unaids.org/en/resources/documents/2016/prevention-gap Accessed 15 July 2016.
    1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed Available at: http://www.who.int/hiv/pub/arv/arv-2016/en/ Accessed 20 June 2016.
    1. Watson JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med 2014; 33:2206–21. - PubMed
    1. Medicines Patent Pool. Progress and achievements 2010–2015 Available at: www.medicinespatentpool.org/wp.../EN_MPP_brochure_and_Insert_2015_web.pdf Accessed 15 June 2016.

MeSH terms